公开(公告)号：US09828427B2

公开(公告)日：2017-11-28

申请号：US14924786

申请日：2015-10-28

Applicant: INNATE PHARMA

Inventor： Nicolas Anfossi ,  Laurent Gauthier ,  Yannis Morel ,  Alessandro Moretta ,  Silvia Parolini ,  Benjamin Rossi

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K45/06

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732

Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.